LRRK2 and Parkinson disease: Some approaches for disease modification target specific proteins (LRRK2 or GCase) or organelles (mitochondria or lysosomes), while others focus on the reduction of aSyn pathology, broadly accepted to be relevant in the majority of sporadic PD patients, by influencing aSyn-production, turnover, aggregation, cell-to-cell propagation, or else influence downstream mechanisms such as neuronal survival or immunomodulation (Vijiaratnam et al. 2021).